X4 PHARMACEUTICALS, INC Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- X4 PHARMACEUTICALS, INC stock issued during period, value, new issues for the quarter ending 2025-09-30 was $86.68M.
- X4 PHARMACEUTICALS, INC stock issued during period, value, new issues for the quarter ending 2025-06-30 was $5.98M.
- X4 PHARMACEUTICALS, INC stock issued during period, value, new issues for the quarter ending 2023-06-30 was $60.44M, a 123253.06% increase year-over-year.
- X4 PHARMACEUTICALS, INC stock issued during period, value, new issues for the quarter ending 2022-09-30 was $13.50M.
- X4 PHARMACEUTICALS, INC stock issued during period, value, new issues for fiscal 2025 was $238.93M.
- X4 PHARMACEUTICALS, INC stock issued during period, value, new issues for fiscal 2023 was $60.44M, a 1.82% increase from fiscal 2022.
- X4 PHARMACEUTICALS, INC stock issued during period, value, new issues for fiscal 2022 was $59.36M, a 19.64% decline from fiscal 2021.
- X4 PHARMACEUTICALS, INC stock issued during period, value, new issues for fiscal 2021 was $73.87M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $238.93M 10-K · filed 2026-03-17 | |
| 2025-09-30 | $86.68M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $5.98M 10-Q · filed 2026-08-06 | |
| 2023-12-31 | $60.44M 10-K · filed 2026-03-17 | |
| 2023-06-30 | $60.44M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $59.36M 10-K · filed 2025-03-26 | |
| 2022-09-30 | $13.50M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $49.00K 10-Q · filed 2022-11-03 | |
| 2022-03-31 | $5.82M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $73.87M 10-K · filed 2024-03-21 | |
| 2021-03-31 | $49.64M 10-Q · filed 2022-11-03 | |
| 2019-06-30 | $79.30M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $0.00 10-K · filed 2021-03-19 | |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-15 | |
| 2017-12-31 | $0.00 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |